Migalastat: all 25 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseaseNot yet recruitingNCT07778667Phase 3
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsRecruitingNCT06904261Phase 3
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseaseCompletedNCT04049760Phase 3Results posted
- Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)CompletedNCT03500094Phase 3Results posted
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseCompletedNCT03425539Phase 3Results posted
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseCompletedNCT02194985Phase 3Results posted
- Open-Label Phase 3 Long-Term Safety Study of MigalastatTerminatedNCT01458119Phase 3Results posted
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseCompletedNCT01218659Phase 3Results posted
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry DiseaseCompletedNCT01196871Phase 2Results posted
- Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseaseCompletedNCT00925301Phase 3Results posted
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 StudyTerminatedNCT00526071Phase 2Results posted
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry DiseaseCompletedNCT00304512Phase 2Results posted
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedNCT00283959Phase 2Results posted
- A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedNCT00283933Phase 2Results posted
- A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedNCT00214500Phase 2Results posted
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseActive, not recruitingNCT04020055Phase 3
- A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart FunctionCompletedNCT03832452Phase 1
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseActive, not recruitingNCT03737214Phase 3
- Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy SubjectsCompletedNCT03380455Phase 1
- A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy SubjectsCompletedNCT02944487Phase 1
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy SubjectsCompletedNCT02944474Phase 1
- A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry DiseaseCompletedNCT02930655Phase 1
- A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy VolunteersCompletedNCT02082327Phase 1
- A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese SubjectsCompletedNCT01853852Phase 1
- Migalastat Food Effect StudyCompletedNCT01489995Phase 1